Allarity Therapeutics secures US patent for stenoparib dosing regimen with protection into 2045
ALLR•Allarity Therapeutics received a US patent covering stenoparib treatment regimens, with protection extending into 2045. Its 36 allowed claims cover twice-daily oral dosing for advanced ovarian cancer and other solid tumors.
1. Patent coverage
The patent covers twice-daily oral stenoparib dosing for advanced ovarian cancer and other solid tumors, including disease resistant to prior therapies. Allarity said the patent supports the dosing strategy used in its ongoing Phase 2 program, which it intends to advance to pivotal trials.




